|
|
|
|
| LEADER |
00000cam a2200000Ii 4500 |
| 001 |
SCIDIR_on1288213769 |
| 003 |
OCoLC |
| 005 |
20231120010624.0 |
| 006 |
m o d |
| 007 |
cr ||||||||||| |
| 008 |
211211t20222022ne a ob 001 0 eng d |
| 040 |
|
|
|a EBLCP
|b eng
|e rda
|e pn
|c EBLCP
|d YDX
|d EBLCP
|d OPELS
|d GZM
|d OCLCO
|d OCLCF
|d TFW
|d SFB
|d OCLCQ
|d OCLCO
|
| 066 |
|
|
|c (S
|
| 019 |
|
|
|a 1287200736
|a 1287209172
|a 1287237397
|
| 020 |
|
|
|a 9780323903639
|
| 020 |
|
|
|a 0323903630
|
| 020 |
|
|
|z 9780323854795
|
| 035 |
|
|
|a (OCoLC)1288213769
|z (OCoLC)1287200736
|z (OCoLC)1287209172
|z (OCoLC)1287237397
|
| 050 |
|
4 |
|a QC463.I44
|
| 082 |
0 |
4 |
|a 615.19
|
| 100 |
1 |
|
|a Agarwal, Shikha,
|e author.
|
| 245 |
1 |
0 |
|a Imidazole-based drug discovery /
|c Shikha Agarwal.
|
| 264 |
|
1 |
|a Amsterdam, Netherlands ;
|a Oxford, United Kingdom ;
|a Cambridge, MA, United States :
|b Elsevier,
|c [2022]
|
| 264 |
|
4 |
|c �2022
|
| 300 |
|
|
|a 1 online resource (xix, 351 pages) :
|b illustrations.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Heterocyclic drug discovery series
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 505 |
8 |
|
|6 880-01
|a 2.3.5 Using benzil, aldehyde, and ammonium acetate -- 2.4 Tetra-substituted imidazole derivatives -- 2.4.1 Using aminoethylpiperazine -- 2.4.2 Using prop-2-ynylamine -- 2.4.3 Using benzil, aldehydes, ammonium acetate, and aniline -- 3 Imidazole hybrids -- 3.1 Imidazole fused heterocycles -- 3.2 Benzimidazole fused heterocycles -- 4 Benzimidazole -- 4.1 Hoebrecker synthesis -- 4.2 Synthesis of benzimidazoles using o -phenylenediamine and acids -- 4.3 Synthesis of benzimidazoles using o -phenylenediamine and acid anhydride -- 4.4 Synthesis of benzimidazoles using o -phenylenediamine and alcohols
|
| 505 |
8 |
|
|a 4.5 Synthesis of benzimidazoles using o -phenylenediamine and alkyl halides -- 4.6 Synthesis of benzimidazoles using ketones -- 4.7 Synthesis of benzimidazoles using o -phenylenediamine and aldehydes -- 5 Conclusion -- Conflict of interest -- Acknowledgments -- Funding source -- References -- Chapter 2 Biological profile of imidazole-based compounds as anticancer agents -- 1 Introduction -- 2 Imidazole-based heterocycles -- 2.1 Imidazole as the main nucleus in the anticancer compounds -- 2.1.1 Mono-substituted imidazole derivatives -- 2.1.2 Disubstituted imidazole derivatives
|
| 505 |
8 |
|
|a 2.1.3 Trisubstituted imidazole derivatives -- 2.1.4 Tetra-substituted imidazole derivatives -- 2.2 Imidazole hybrids as anticancer agents -- 2.3 Imidazole fused heterocycles -- 2.3.1 Imidazole fused heterocycles -- 2.3.2 Benzimidazole fused heterocycles -- 2.4 Imidazole-based metal complexes as anticancer agents -- 3 Conclusion and future challenges -- Conflict of interest -- Acknowledgment -- Funding source -- References -- Chapter 3 Recent advancements on imidazole containing heterocycles as antitubercular agents -- 1 Introduction -- 2 Imidazole-based heterocycles -- 2.1 Substituted imidazoles
|
| 505 |
8 |
|
|a 2.2 Hybrid Imidazoles -- 2.3 Fused imidazoles -- 2.4 Linker imidazole -- 2.5 Benzimidazole -- 3 Conclusion -- Conflict of interest -- Acknowledgments -- Funding source -- References -- Chapter 4 Imidazole derivatives: Impact and prospects in antiviral drug discovery -- 1 Introduction -- 2 Imidazole derivatives and their action against different viruses -- 2.1 Zika virus -- 2.2 Influenza -- 2.3 SARS-COVID -- 2.4 Dengue -- 2.5 Hepatitis -- 2.6 HIV -- 2.7 Miscellaneous -- 3 Conclusion -- Acknowledgments -- Conflict of interest -- Funding source -- References
|
| 500 |
|
|
|a Chapter 5 Imidazole heterocycles: Therapeutically potent lead compounds as antimicrobials.
|
| 588 |
0 |
|
|a Online resource; title from PDF title page (ScienceDirect platform, viewed April 19, 2022).
|
| 650 |
|
0 |
|a Imidazoles.
|
| 650 |
|
0 |
|a Drugs.
|
| 650 |
|
0 |
|a Drug development.
|
| 650 |
|
2 |
|a Imidazoles
|0 (DNLM)D007093
|
| 650 |
|
2 |
|a Pharmaceutical Preparations
|0 (DNLM)D004364
|
| 650 |
|
6 |
|a Imidazole.
|0 (CaQQLa)201-0026559
|
| 650 |
|
6 |
|a M�edicaments.
|0 (CaQQLa)201-0002990
|
| 650 |
|
6 |
|a M�edicaments
|x D�eveloppement.
|0 (CaQQLa)201-0306620
|
| 650 |
|
7 |
|a Drug development
|2 fast
|0 (OCoLC)fst00898670
|
| 650 |
|
7 |
|a Drugs
|2 fast
|0 (OCoLC)fst00898761
|
| 650 |
|
7 |
|a Imidazoles
|2 fast
|0 (OCoLC)fst01715755
|
| 776 |
0 |
8 |
|i Print version:
|z 0323854796
|w (OCoLC)1257403690
|
| 830 |
|
0 |
|a Heterocyclic drug discovery.
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780323854795
|z Texto completo
|
| 880 |
0 |
|
|6 505-01/(S
|a Intro -- Imidazole-Based Drug Discovery -- Copyright -- Dedication -- Contents -- Contributors -- About the authors -- Preface -- Acknowledgments -- Chapter 1 Imidazole and its derivatives: Introduction and synthetic aspects -- 1 Introduction -- 2 Synthesis of substituted imidazoles -- 2.1 Mono-substituted imidazole derivatives -- 2.2 Di-substituted imidazole derivatives -- 2.3 Tri-substituted imidazole derivatives -- 2.3.1 Using 2,3-diaminomaleonitrile -- 2.3.2 Using the Van Leusen method -- 2.3.3 Using 2,3-dioxo-3-substituted propanoates -- 2.3.4 Using α -aminoketones
|
